ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

ADVFN

Trade Now

EasyMarkets
Market Data
News
Tools
Markets
Discover
Subscribe Login/Register Profile Icon
S&P 500
4,567.18
(
-0.06%
)
US Tech 100
15,490.40
(
0.24%
)
Dow Jones
36,124.56
(
-0.22%
)
Brent Oil
77.075
(
-1.49%
)
Bitcoin
43,918.95
(
4.59%
)
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. AIM ImmunoTech Inc (AIM)

  7. AIM ImmunoTech Inc (AIM) News

AIM AIM ImmunoTech Inc

0.4899
0.0399 (8.87%)
After Hours
Last Updated: 16:22:26
Delayed by 15 minutes
Company Name Stock Ticker Symbol Market Type
AIM ImmunoTech Inc AIM AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
Upgrade Icon
0.0399 8.87% 0.4899 16:22:26
Open Price Low Price High Price Close Price Prev Close
0.4548 0.4402 0.48 0.4731 0.45
more quote information »

Recent News

Date Time Source Heading
11/28/202316:54EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/28/202316:30BWAIM ImmunoTech Provides Update Regarding Annual Meeting
11/27/202312:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/27/202309:05GLOBEAIM ImmunoTech Bolsters Intellectual Property Estate for..
11/21/202312:00GLOBEAIM ImmunoTech Completes Treatment of Last Subject in Phase..
11/20/202317:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/20/202309:05EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
11/20/202307:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/16/202309:21EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
11/15/202307:30EDGAR2Form 8-K - Current report
11/15/202307:30GLOBEAIM ImmunoTech Reports Third Quarter 2023 Financial Results..
11/14/202310:00GLOBEAIM ImmunoTech Announces Publication of Data from Roswell..
11/09/202308:05GLOBEAIM ImmunoTech to Discuss Third Quarter 2023 Financial..
11/08/202316:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/08/202308:45EDGAR2Form 8-K - Current report
11/08/202308:45GLOBEAIM ImmunoTech Announces Encouraging Translational Data from..
11/07/202306:03EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
11/06/202309:25BWAIM ImmunoTech Files Definitive Proxy Statement and Sends..
11/06/202309:09EDGAR2Form DEFC14A - Definitive proxy statement, contested..
11/01/202317:01EDGAR2Form DEFC14A - Definitive proxy statement, contested..
10/30/202308:55GLOBEAIM ImmunoTech Announces Abstract Accepted for Poster..
10/24/202317:00EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
10/17/202308:45GLOBEAIM ImmunoTech Engages Business Development Firm, Azenova,..
10/13/202316:57EDGAR2Form PREC14A - Preliminary proxy statements, contested..
10/10/202309:00EDGAR2Form PREC14A - Preliminary proxy statements, contested..
9/29/202315:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/29/202307:00EDGAR2Form 8-K - Current report
9/22/202309:10EDGAR2Form 8-K - Current report
9/22/202309:05GLOBEAIM ImmunoTech Selected to Present at the 3rd Annual Marie..
9/11/202313:00GLOBEAIM ImmunoTech Announces Report of Complete Topline Data..
9/05/202309:05GLOBEAIM ImmunoTech to Present at the H.C. Wainwright 25th Annual..
8/28/202312:52EDGAR2Form DFAN14A - Additional definitive proxy soliciting..
8/28/202306:36EDGAR2Form SC 13D/A - General statement of acquisition of..
8/25/202314:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
8/23/202316:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
8/23/202308:51EDGAR2Form 8-K - Current report
8/23/202308:00BWAIM ImmunoTech Rejects Director Nomination Notice from..
8/15/202307:00EDGAR2Form 8-K - Current report
8/15/202306:45GLOBEAIM ImmunoTech Reports Second Quarter Financial Results and..
8/14/202317:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/09/202309:05GLOBEAIM ImmunoTech to Discuss Second Quarter 2023 Financial..
8/08/202308:05GLOBEAIM ImmunoTech Announces Completion of Enrollment in Phase 2..
8/07/202316:15EDGAR2Form SC 13D/A - General statement of acquisition of..
7/27/202317:01EDGAR2Form SC 13D - General statement of acquisition of beneficial..
7/18/202319:30GLOBEAIM ImmunoTech Issues Notice that an Unaffiliated Third..
7/17/202319:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
7/10/202316:45EDGAR2Form 8-K - Current report
7/10/202308:05GLOBEAIM ImmunoTech Enrolls and Doses First Subject in Phase 2..
7/05/202308:35GLOBEAIM ImmunoTech to Participate in the Virtual Investor Summer..
7/03/202308:42EDGAR2Form S-8 - Securities to be offered to employees in employee..

Your Recent History

AMEX
AIM
AIM ImmunoTech
Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com